ONC

#400
BeOne Medicines Ltd - American Depositary Shares
287.9 2 USD
-0.92%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
287.92
287.92
Range Annuel
3.05
385.22
Changement quotidien
-0.92%
Changement Mensuel
-1.17%
Evolution sur 6 mois
-14.91%
Changement Annuel
-8.80%
Clôture Précédente
290.5 8
Open
287.9 2
Low
287.9 2
High
287.9 2
Volume
36
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur 202020212022202320242025 TTM

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.